Fubotv earnings beat by $0.10, revenue topped estimates
In Friday’s trading session, Cathie Wood’s ARK ETFs made several notable moves, with the most significant being the purchase of shares in 10X Genomics Inc (NASDAQ:TXG) and Intellia Therapeutics Inc (NASDAQ:NTLA), as well as the sale of shares in Tesla Inc (NASDAQ:TSLA) and Adaptive Biotechnologies Corp (NASDAQ:ADPT).
Cathie Wood’s ARK ETF published their daily trades for Friday, May 30th, 2025, revealing a mix of both bullish and bearish bets in the biotech and tech sectors. The largest transaction of the day was the acquisition of 342,179 shares of 10X Genomics Inc, valued at approximately $3.2 million, split between the ARKK and ARKG ETFs. This move underscores ARK’s confidence in the genomic company, which has been a recurring interest for the investment firm.
Following closely, ARK also increased its position in Intellia Therapeutics Inc by purchasing 226,513 shares. The transaction, totaling around $1.7 million, was divided between ARKK and ARKG, indicating a growing focus on the gene-editing company which has seen consistent buying in recent days.
On the sell side, ARK trimmed its holdings in Tesla Inc, offloading 6,511 shares with a total value of roughly $2.3 million. This sale comes amidst a series of recent reductions in the electric vehicle giant, perhaps signaling a strategic shift or rebalancing in ARK’s portfolio.
Additionally, ARK continued its sell-off of Adaptive Biotechnologies Corp, parting with 164,741 shares through its ARKG ETF, amounting to over $1.5 million. This continues a trend of divestment from Adaptive, as seen in previous trading days.
Other transactions included the sale of 48,371 shares of 3D Systems Corp (NYSE:DDD) across ARKQ and ARKX (NYSE:ARKX) ETFs, totaling approximately $77,393. The sale extends a pattern of ARK reducing exposure to the 3D printing company, with significant sales executed in the past week.
Investors and analysts closely monitor ARK’s daily trades for insights into Wood’s strategy and the potential growth trajectories of the included companies. The continued investment in genomic and biotech companies like Intellia Therapeutics and 10X Genomics reflects a long-term bullish outlook in these sectors, while the divestments from companies like Tesla and Adaptive Biotechnologies suggest a reallocation of resources within ARK’s innovative and disruptive technology-focused portfolios.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.